Detalles de la búsqueda
1.
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Breast Cancer Res Treat
; 195(3): 275-287, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35915198
2.
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(6): 763-775, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32353342
3.
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Oncologist
; 25(9): e1346-e1354, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32536013
4.
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Oncologist
; 25(2): e243-e251, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043763
5.
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.
BMC Cancer
; 20(1): 855, 2020 Sep 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32894087
6.
Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
BMC Health Serv Res
; 14: 555, 2014 Nov 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-25392276
7.
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Curr Med Res Opin
; 38(8): 1319-1331, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35535675
8.
Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.
Patient Prefer Adherence
; 15: 2417-2429, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34764640
9.
Development of a Prognostic Factor Index Among Women With HR+/HER2- Metastatic Breast Cancer in a Community Oncology Setting.
Clin Breast Cancer
; 21(4): 317-328.e7, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33678566
10.
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.
Expert Rev Pharmacoecon Outcomes Res
; 21(4): 699-710, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32755262
11.
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Front Oncol
; 11: 810023, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35223458
12.
Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
Curr Med Res Opin
; 35(10): 1699-1710, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31060392
13.
Systematic Review of Brain Metastases in Patients With Non-Small-Cell Lung Cancer in the United States, European Union, and Japan.
Clin Lung Cancer
; 18(6): 607-614, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28571688
14.
A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Leuk Res
; 61: 89-95, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28934680
15.
Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
PLoS One
; 9(3): e90299, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24618579
16.
Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using medicare current beneficiary survey data.
Patient
; 6(3): 189-200, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23828691
Resultados
1 -
16
de 16
1
Próxima >
>>